In conclusion, our data suggest that, compared with a DPP-4 inhibitor plus metformin, treatment with a sulfonylurea derivative plus metformin was associated with increased risks of total CVD, MI, and ischemic stroke. Here, DPP4 is linked to ischemic stroke.